Clinical observations during adjunctive Cannabis treatment and subsequent oclacitinib dose reduction in dogs with atopic dermatitis.
4 affiliations
- 1Postgraduate Program in Veterinary Medicine, Federal University of Santa Maria (PPGMV-UFSM), Santa Maria, Rio Grande do Sul, Brazil.
- 2Postgraduate Program in Conventional and Integrative Veterinary Medicine (PPGMVCI), Federal University of Santa Catarina (UFSC), Curitibanos, Santa Catarina, Brazil.
- 3Department of Statistics, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.
- 4Department of Small Animal Medicine, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.
Abstract
Canine atopic dermatitis is a multifactorial chronic skin disease that is difficult to control and requires lifelong and multimodal therapy. Cannabis has regained medical relevance in several fields, particularly in dermatology, as the endocannabinoid system is uniquely expressed in skin tissues and cells. Modulation through cannabinoids aims to restore skin homeostasis by reducing oxidative stress, inflammation, and consequently the clinical signs exhibited by animals with dermatopathies. This study aimed to evaluate Cannabis oil as a therapeutic option for dogs with atopic dermatitis, for both managing recurrent clinical signs and for enabling oclacitinib dose reduction. Sixteen dogs with atopic dermatitis previously treated with oclacitinib without satisfactory improvement were selected. All dogs underwent a fixed-sequence repeated-measures protocol consisting of four standardized evaluation stages: T0 (oclacitinib alone), T30 (placebo + oclacitinib), T60 (Cannabis oil + oclacitinib), and T90 (Cannabis oil + oclacitinib at 50% reduced dose). Dermatological assessments were performed at each stage to monitor clinical progression and response, including CADESI-4, performed by a veterinary dermatologist, and pruritus scoring, reported by the owners; both were blinded to whether the animal was receiving placebo (mineral oil) or Cannabis oil. Of the 16 enrolled dogs, fourteen completed all study stages through T90. No statistically significant difference was observed for CADESI-4. Likewise, no significant difference in pruritus was observed between T30 (placebo) and T60 (Cannabis oil); however, a significant reduction in pruritus was found between T0 x T60 (p = 0.0010), and T0 x T90 (p = 0.0025). Mild, transient, and self-limiting adverse events, as reported by the owners, were observed during both the placebo and Cannabis oil treatment periods. It is concluded that adjunctive Cannabis oil contributed to improved pruritus control in dogs with atopic dermatitis. In addition, maintenance of pruritus scores was observed following a predefined 50% reduction in oclacitinib dosage, supporting further investigation of Cannabis oil as part of a multimodal therapeutic strategy for canine atopic dermatitis.
Related
- Patient perspective on adjunctive treatment for early onset scoliosis
- Conservative Treatment with Adjunctive Use of Teriparatide for Periprosthetic Humeral Fractures after Reverse Total Shoulder Arthroplasty: A Report of 6 Cases
- Vitiligo developing during dupilumab treatment in a child with atopic dermatitis: a case report and literature review
- Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature
- Efficacy of cryotherapy as an adjunctive treatment for mandibular central giant cell granuloma: A case series
BibTeX
@article{mariga2026clinical,
title = {{Clinical observations during adjunctive Cannabis treatment and subsequent oclacitinib dose reduction in dogs with atopic dermatitis.}},
author = {Carollina Mariga and Filipe Costa da Silva and Otávio Henrique de Melo Schiefler and Erik Amazonas and Ana Lucia Souza Silva Mateus and Claudete Schmidt and Saulo Tadeu Lemos Pinto Filho},
journal = {Frontiers in allergy},
year = {2026},
month = oct,
doi = {10.3389/falgy.2026.1852631},
url = {https://europepmc.org/article/MED/42952978},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical observations during adjunctive Cannabis treatment and subsequent oclacitinib dose reduction in dogs with atopic dermatitis.
AU - Carollina Mariga
AU - Filipe Costa da Silva
AU - Otávio Henrique de Melo Schiefler
AU - Erik Amazonas
AU - Ana Lucia Souza Silva Mateus
AU - Claudete Schmidt
AU - Saulo Tadeu Lemos Pinto Filho
PY - 2026
DA - 2026/10/14
JO - Frontiers in allergy
DO - 10.3389/falgy.2026.1852631
UR - https://europepmc.org/article/MED/42952978
AB - Canine atopic dermatitis is a multifactorial chronic skin disease that is difficult to control and requires lifelong and multimodal therapy. Cannabis has regained medical relevance in several fields, particularly in dermatology, as the endocannabinoid system is uniquely expressed in skin tissues and cells. Modulation through cannabinoids aims to restore skin homeostasis by reducing oxidative stress, inflammation, and consequently the clinical signs exhibited by animals with dermatopathies. This study aimed to evaluate Cannabis oil as a therapeutic option for dogs with atopic dermatitis, for both managing recurrent clinical signs and for enabling oclacitinib dose reduction. Sixteen dogs with atopic dermatitis previously treated with oclacitinib without satisfactory improvement were selected. All dogs underwent a fixed-sequence repeated-measures protocol consisting of four standardized evaluation stages: T0 (oclacitinib alone), T30 (placebo + oclacitinib), T60 (Cannabis oil + oclacitinib), and T90 (Cannabis oil + oclacitinib at 50% reduced dose). Dermatological assessments were performed at each stage to monitor clinical progression and response, including CADESI-4, performed by a veterinary dermatologist, and pruritus scoring, reported by the owners; both were blinded to whether the animal was receiving placebo (mineral oil) or Cannabis oil. Of the 16 enrolled dogs, fourteen completed all study stages through T90. No statistically significant difference was observed for CADESI-4. Likewise, no significant difference in pruritus was observed between T30 (placebo) and T60 (Cannabis oil); however, a significant reduction in pruritus was found between T0 x T60 (p = 0.0010), and T0 x T90 (p = 0.0025). Mild, transient, and self-limiting adverse events, as reported by the owners, were observed during both the placebo and Cannabis oil treatment periods. It is concluded that adjunctive Cannabis oil contributed to improved pruritus control in dogs with atopic dermatitis. In addition, maintenance of pruritus scores was observed following a predefined 50% reduction in oclacitinib dosage, supporting further investigation of Cannabis oil as part of a multimodal therapeutic strategy for canine atopic dermatitis.
SN - 2673-6101
ER -